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The adverse effects and choice of injectable agents in MDR-TB: amikacin or capreomycin 19 
Abstract 20 
Background: The prolonged use of injectable agents in an MDR-TB regimen is recommended 21 
by the WHO despite association with ototoxicity and nephrotoxicity.  22 
Objective: We undertook this study to look at the relative adverse effects of capreomycin 23 
and amikacin.  24 
Methods: We reviewed the case notes of 100 consecutive patients treated at 4 MDR-TB 25 
treatment centres in the UK.  26 
Results: The median total duration of treatment with an injectable agent was 178 (IQR 109-27 
192, n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB 28 
plus fluoroquinolone resistance and 558 (324-735, n=8) days for those with XDR-TB. 29 
Injectable use was longer for those started with capreomycin at 183 (IQR 123-197) days 30 
compared to 119 (IQR 83-177) days with amikacin (p=0.002). Excluding XDR-TB, 51 (51/85, 31 
60%) patients were treated with an injectable for over 6 months and 12 (12/85, 14%) for 32 
over 8 months. 40 % of all patients discontinued the injectable due to hearing loss. 55% of 33 
patients experienced ototoxicity: 5 times (hazard ratio (HR) 5.2, CI 1.2-22.6, p=0.03) more 34 
likely in those started on amikacin compared to treatment with capreomycin only. Amikacin 35 
was associated with less hypokalemia than capreomycin (Odds ratios: 0.28 (0.11-0.72)), with 36 
5 (5/37, 14%) patients stopping capreomycin due to recurrent electrolyte loss. There was no 37 
difference in the number experiencing a creatinine rise of > 1.5 times baseline.  38 
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 39 
Conclusion: Hearing loss is frequent in this cohort, though significantly lower in those 40 
starting capreomycin which should be given greater consideration as a first line agent.  41 
Main Text 42 
Introduction 43 
Treatment of multidrug resistant tuberculosis (MDR-TB) is challenging requiring extensive 44 
multidrug combinations for up to two years associated with significant adverse effects(1) 45 
Current treatment for MDR-TB is largely dependent on the World Health Organisation 46 
(WHO) guidelines(2-4)  which are based on cohort, meta-analysis data and expert opinion. 47 
These recommend that all patients should be initially (intensive phase) treated with an 48 
injectable agent in the form of an aminoglycoside (kanamycin/amikacin) or polypeptide 49 
(capreomycin). The duration of the intensive phase recommended by the WHO rose from a 50 
minimum of 6 months to 8 months in 2011(3, 4) with even longer durations recommended 51 
for cases with more extensive resistance.  The recommendation was based on a large meta-52 
analysis of patient outcomes and did not take into account the side effects or other costs of 53 
these drugs.(5)  54 
The injectable agents have significant side effects in the form of permanent and potentially 55 
progressive post cessation ototoxicity and usually reversible nephrotoxicity. (6-9) The 56 
frequency of ototoxicity and nephrotoxicity experienced by patients varies between studies, 57 
and most focus on the side effects of the aminoglycosides rather than the polypeptide, 58 
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capreomycin. Limited evidence suggests that capreomycin may be less ototoxic than 59 
amikacin.(10) 60 
No randomised controlled trial of different injectable agents has been performed but better 61 
data is needed to inform policy. We performed a detailed service evaluation cohort study 62 
within four specialist UK MDR-TB treatment centres to compare the outcomes with different 63 
injectable agents in a real world setting. 64 
Methods 65 
 66 
Setting 67 
Retrospective data were collected through clinical records and hospital database review at 4 68 
tuberculosis (TB) treatment centres; St Mary’s Hospital, Imperial College NHS Trust, London 69 
(centre 1), Heartlands Hospital, Birmingham (centre 2), the Royal Free Hospital, London 70 
(centre 3), St George’s Hospital, London (centre 4). These centres act as regional referral 71 
hubs for MDR-TB treatment . Data were also collected at referring hospitals if patients were 72 
treated under a shared care model. Standard definitions were used for MDR-TB and 73 
extensively drug resistant tuberculosis (XDR-TB), pulmonary (PTB), extra pulmonary 74 
tuberculosis (EPTB)(11) and treatment was based on the WHO guidelines.(2, 3) At sites 1-2 75 
amikacin is the preferred injectable agent, site 3 uses a mix and site 4 predominantly uses 76 
capreomycin (all intravenous).  All sites switched injectable at the physician’s discretion. All 77 
injectable agents are dosed initially at 15mg/kg once a day with trough drugs levels for 78 
amikacin at least weekly. Reduced frequency of dosing is used if side effects occur. Duration 79 
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of 6 months or more was defined as over 160 days and duration of 8 months was defined as 80 
over 220 days. 81 
Study population and eligibility criteria 82 
The first 100 consecutive patients, over 14 years of age, with a diagnosis of MDR-TB made in 83 
the UK, initiating MDR-TB treatment at the four sites between 2008 and 2014, were 84 
reviewed. Seven patients were excluded due to: lack of injectable agent use (2), 85 
streptomycin use at start (2), and over three initiations on MDR-TB medications (n=3). The 86 
cohort was split into two according to date of treatment start (the 51st patient started 87 
treatment in spring 2011) which corresponded to the change in WHO advice regarding 88 
injectable duration. 89 
 90 
Renal function monitoring 91 
To be included in analysis of renal function patients required at least weekly blood results 92 
available for review. Renal impairment was defined as mild at 1.5 times baseline creatinine 93 
and severe at over 3 times baseline(12). Hypokalaemia was defined as any drop below 94 
3.5mmol/L.(13) Hypomagnesaemia was defined as any measurement below 0.7mmol/L.(12) 95 
Audiological monitoring 96 
All patients underwent pure tone audiometry (PTA) performed to the standards of the 97 
British Society of audiology (14) at the start of the injectable therapy. All sites performed 98 
PTA if hearing loss/change symptoms/any concern about hearing arose on treatment and 99 
sites 1, 2 and 3 had a policy of monthly PTA in addition (limited by patient adherence to 100 
protocol). Centre 3 performed audiograms at frequencies above 9- 20khz for a proportion of 101 
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the study period. Significant deterioration between audiograms was determined by the 102 
American speech and hearing association (ASHA) criteria which were as follows for 103 
frequencies tested between 250-8khz: (i) 20dB decrease ay any one test frequency, (ii) 10 104 
dB decrease at any two adjacent frequencies, (iii). Loss of response at any three adjacent 105 
frequencies where responses were previously obtained .(15) Two end points relating to 106 
hearing were chosen: an audiogram definition (ototoxicity) and a composite definition 107 
encompassing audiogram results and clinically reported hearing loss (hearing loss 108 
(composite)) (Table 1). Patient reported ‘hearing impairment’ was defined as any report by 109 
the patient of a negative change in hearing while on injectable agents or after stopping the 110 
injectable as documented by a nurse or doctor. ‘Tinnitus’ was defined as any symptoms 111 
reported by the patient that were interpreted as tinnitus by a doctor or nurse and 112 
documented in the records. Reasons for stopping injectable agents were collated from the 113 
medical notes according to what was written by the consultant in charge of treatment.  114 
 115 
Statistics  116 
Patients were grouped according to the injectable agent they were exposed to: 1. 117 
capreomycin only, 2. amikacin start (includes those only treated with amikacin and those 118 
treated with amikacin and switched to capreomycin or streptomycin because hearing loss 119 
was the main driver of this switch), 3. capreomycin then switch to amikacin (none switched 120 
due to hearing loss). Hearing loss was analysed within survival settings using Cox 121 
proportional hazard models, modelling the time since treatment start to point of hearing 122 
loss. Raised creatinine and hypokalaemia were investigated using logistic regression. 123 
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Univariate analyses were initially undertaken which included all variables collected (age, 124 
gender, baseline creatinine, baseline creatinine clearance (Cockroft Gault equation), dose of 125 
drug, MDR-TB type, number of amikacin troughs, centre, and amikacin and capreomycin 126 
group). Associations with resulting p-values less than 0.1 were further considered to form a 127 
multivariable/adjusted models based on similar numbers of complete observations. Model 128 
selection was undertaken by choosing the most parsimonious model using Akaike 129 
information criteria (AIC) and Bayesian information  criteria (BIC). The final models were 130 
further refined using multiple imputation methodologies assuming missing at random 131 
model   to account for approximately 15% of the original data that  was missing (16). Further 132 
details on statistical methodologies are given in appendix 1. STATA software was employed 133 
for data analyses (StataCorp.2015 Stata Statistical Software: Release 14. College Station, 134 
TX:StataCorp LP).  135 
 136 
Ethics 137 
The study was deemed to be a service evaluation at the NHS ethics board (NRES committee 138 
London- City and East). Consent was given by the Confidentiality Advisory Group (GAG) for 139 
access to clinical records review. The data were anonymised onsite for off sites analyses. 140 
 141 
Results  142 
Fifty-four patients were started on amikacin and 39 were started on capreomycin (total, 143 
n=93). Nineteen patients switched injectable agent for the reasons stated in Figure 1. 144 
Background demographics and tuberculosis characteristics can be seen in Table 2.  145 
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Total duration of treatment with an injectable agent 146 
The median total duration of treatment with an injectable agent was 178 (IQR 109-192, 147 
n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus 148 
fluroquinolone resistance (MDR-TB +FLQ) and 558 (324-735, n=8) for those with XDR-TB.  149 
 150 
Excluding those with XDR-TB, 51 (51/60, 60%) patients were treated for 6 months or more 151 
and 12 (12/85, 14%) for 8 months or more. In the early cohort the median duration of 152 
treatment was 165 (107-187, n=42) days, of which 23 (23/42, 55%) achieved the target of 6 153 
months and 3 (3/42, 7%) were treated for 8 months plus. In the latter cohort the median 154 
duration of treatment was 183 (109-210, n=43) days, of which 28 (28/43, 65%) were treated 155 
for 6 months or more and 9 (9/43, 21%) achieved the target of 8 months or more. There was 156 
no statistical difference in duration between the early and late cohort (p=0.19).  157 
Seven (7/8, 87%) patients with XDR-TB were treated for 6 months or more and 6 (6/8, 75%) 158 
for 8 months or more.  159 
The reasons for not achieving 6 months of treatment or more for all groups of patients were 160 
hearing loss (composite) 14 (14/35, 40%), physician choice 8 (8/35, 23%), resistance 4 (4/35, 161 
11%), compliance concerns 3 (3/35, 9%) other 6 (6/35, 17%).  162 
The median duration of the first line injectable agent was 160 (IQR 91-186) days for all 163 
patients. The median total duration was 183 (IQR 123-197) days for those started on 164 
capreomycin and 119 (IQR 83-177) days for those started on amikacin (p=0.002). 165 
166 
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Ototoxicity 167 
The proportion of cases that met the criteria for ototoxicity assessment was 55 (55/93, 59%) 168 
(Table 1) of whom 39 were started on amikacin and 16 started on capreomycin. Clinical 169 
notes were available for all 55 patients.  Ototoxicity occurred in 30 patients (30/55, 55%), at 170 
a median duration of 112.5 days (IQR 91-177) and 18 (18/55, 60%) had bilateral changes. 171 
Deterioration was seen at the frequencies 6 -8 kHz only in 19 (19/55, 63%) cases, in the 172 
frequencies 4-8kHz only in 3 (3/55, 10%) cases, in frequencies 2-8kHz only in 6 (6/55, 20%) 173 
cases and across all frequencies tested (250Hz-8kHz) in 2 (2/55, 7%) cases. The median 174 
maximum change from baseline hearing at the worst effected frequency was 40 dB (IQR 25-175 
55).  At the time that ototoxicity was detected 8 (8/55, 27%) patients reported new onset 176 
hearing disturbance and tinnitus, 8 (8/55, 27%) reported tinnitus only, 3 (3/55, 10%) 177 
reported hearing disturbance only and 11 (11/55, 37%) did not report any symptoms. 178 
 179 
Ototoxicity occurring on Amikacin 180 
Twenty-eight cases of ototoxicity occurred while on treatment with amikacin (n=23) or after 181 
stopping treatment with amikacin (n=5). The median total number of amikacin trough levels 182 
did not differ between those with ototoxicity (1.03 IQR 0.77-1.28) and those without (1.21 183 
IQR 1-1.43) (p=0.10). The proportion of one or more amikacin trough levels above 2.5 was 184 
12/28 (40%) for those with ototoxicity and 5/14 (36%) for those treated with amikacin and 185 
no ototoxicity (P=0.66).  186 
 187 
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3 cases experienced ototoxicity on amikacin and had initially been treated with 188 
capreomycin. They had been switched to amikacin due to electrolyte disturbance (n=2) or 189 
resistance (n=1). Two of the patients had normal audiograms (and same as their baseline) at 190 
the time of switch (174 and 164 days) and the third had a normal audiogram at the start of 191 
capreomycin followed by an abnormal audiogram after 282 days of amikacin treatment 192 
when newly reported tinnitus lead to testing. Fifteen (15/28, 54%) patients had sufficient 193 
audiograms to assess deterioration after stopping amikacin; 10 (10/15, 67%) progressed, 1 194 
(1/28, 7%) improved and 4 (4/15, 27%) did not change. 195 
 196 
Ototoxicity occurring on Capreomycin 197 
Two cases of ototoxicity occurred on capreomycin. Both were in patients with XDR-TB in 198 
whom stopping the regimen would have reduced the number of active drugs below 4 and so 199 
despite early detection, treatment was continued with monitoring. Neither case 200 
experienced any permanent symptoms. Both cases had normal audiograms on first 201 
assessment and sensorineural hearing loss was identified on the second audiogram to be 202 
performed after the baseline which was at day 33 (performed due to vague symptoms of 203 
muffled hearing which went away) and day 112 (performed for screening no symptoms) of 204 
treatment respectively. Changes were seen bilaterally in both cases at the 6KHz and 8KHz 205 
frequency. There was a drop of 10-20db in case 1 and a drop of 30-55db in case 2. A further 206 
3 and 4 audiograms were performed until days 434 (case 1) and 447 (case 2) of treatment 207 
and no further deterioration was seen. Both patients continued treatment after this period 208 
of monitoring with no change in symptoms but no further audiograms were performed.209 
210 
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Multivariable analysis using only the patients who fitted the ototoxicity criteria showed that 211 
ototoxicity was five times more likely for patients started on amikacin than for those treated 212 
with only capreomycin (HR 5.2, CI 1.2-22.6, p=0.03). 213 
 214 
Hearing loss (composite) 215 
Three patients (3/93) did not have sufficient medical notes (n=1) or could not express loss of 216 
hearing (psychosis n=1, intubated n=1) to be included in this analysis. Thirty-four (34/90, 217 
38%) of those meeting criteria for inclusion experienced hearing loss (composite). The 218 
multivariable analysis showed that the likelihood of hearing loss (composite) was 14 times 219 
greater for patients started on amikacin compared to those treated with capreomycin only 220 
(Hazard ratio 13.9  CI 3.25-59, P<0.001) (Table 3) . Predicted survival analysis also showed 221 
that the probability of not developing hearing loss beyond 90 days was 0.99 (0.95- 1.00) in 222 
those on capreomycin only compared to 0.85 (0.73-0.92) for those starting amikacin. 223 
Furthermore the probability of surviving without hearing loss beyond 180 days was 0.97 224 
(0.86-0.99) for those on capreomycin only compared to 0.58 (0.41, 0.72) for those started 225 
on amikacin (Figure 2).   226 
 227 
Nephrotoxicity 228 
Over the first 3 months renal function monitoring was performed a median of 19 times (IQR: 229 
14-25) and over months 4-6, 9 times (IQR: 4-15).  230 
 231 
Raised creatinine 232 
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Eighty-five cases had complete set of creatinine blood results. 25% (21/85) had a rise of 1.5 233 
times or more from baseline of which 3 (3.5% =3/85) had a rise of 3 times baseline. The 234 
creatinine returned to baseline (under 1.5 times normal) in 19 (19/21) cases, 16 before the 235 
end of the injectable and 3 before the end of MDR-TB treatment. In patients where the 236 
creatinine did not return to baseline; one required haemodialysis after the amikacin was 237 
stopped (he already had chronic kidney disease at the start of therapy for MDR-TB and a 238 
baseline creatinine of 313 µmol/L which peaked at 846µmol/L) and the other due to death 239 
from advanced HIV (CD4=5). A multivariable model including baseline creatinine, duration 240 
on injectable agent and choice of injectable agent at start showed that there was no 241 
significant difference in the odds of raised creatinine between the two injectable agents 242 
chosen at the start (p=0.178) when adjusted for the total duration of the treatment. 243 
However, some evidence suggests that increasing duration may increase the odds of raised 244 
creatinine, i.e. 30 days increase is associated with 15% (95%CI(25, 32%)) raise in the odds of 245 
raised creatinine (p=0.04)  (Table 4).  246 
 247 
Electrolyte disturbance 248 
 249 
Eighty-six patients  had a complete set of potassium results, 37 started on capreomycin and 250 
49  amikacin. Hypokalaemia was found in 38 (38/86, 44%) patients while on an injectable 251 
agent: 23 (23/38, 61%) were on capreomycin and 15 (15/38, 39%) amikacin.Eighteen cases 252 
(18/38) resolved alone without potassium replacement.  Seventeen required replacement 253 
with oral potassium (13/17 on capreomycin), 7 required replacement with intravenous 254 
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potassium (all capreomycin), 4 had their dose reduced to 3 times per week (all capreomycin) 255 
and 3 required a switch in injectable agent (all capreomycin to amikacin). A multivariable 256 
model including duration of injectable agent and initial injectable agent indicated that the 257 
odds of hypokalaemia were approximately 4 times lower in those starting amikacin than for 258 
those starting capreomycin (Odds ratios: 0.28 (0.11-0.72). (Table 4) 259 
 260 
Regular magnesium testing was performed for 15 of the capreomycin and none of the 261 
amikacin patients. Thirteen  (13/15) were hypomagnesemic (11/13 with a reading below 0.5 262 
mmol/L) of which 10 were treated with oral replacement, 9 with intravenous replacement 263 
and 4 required a switch to amikacin (3 of these also had reduced potassium and are 264 
inclusive of the 3 above). One stopped injectable earlier than planned due to 265 
hypomagnesaemia.  266 
 267 
Switching from capreomycin to amikacin or stopping capreomycin early for electrolyte 268 
disturbance occurred in 5 patients (5/37) at a median of 132 (range 53-207, n=5) days. Of 269 
the four cases switched from capreomycin to amikacin one subsequently suffered 270 
ototoxicity on amikacin.  271 
 272 
Discussion 273 
We present data showing that ototoxicity is very frequent and that in England a third of 274 
patients do not reach the original 2008 WHO treatment guideline advising at least 6 months 275 
of an injectable agent. Even fewer reach the newer target of 8 months for the intensive 276 
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phase. In a sub-cohort analysis capreomycin is associated with less ototoxicity and/or 277 
hearing loss than amikacin though its use is sometimes limited by electrolyte disturbance. 278 
Those starting capreomycin were also able to tolerate injectable treatment for much longer.  279 
Hearing loss during MDR-TB treatment is reported to be anywhere between 4.4% (1, 17)and 280 
62% (18) (19) dependent on duration, drug choice, dose(6) and type of monitoring. Studies 281 
with a clinical definition (patient reporting symptoms) show lower levels than those with an 282 
audiogram based definition (20) and the majority of studies have been performed in the 283 
presence of the aminoglycosides, amikacin or the more commonly used worldwide and 284 
closely related kanamycin (15mg/kg/day). Our level of 55% ototoxicity is similar to the 285 
findings of others using intense monitoring and aminoglycosides at 15mg/kg, (15) (7, 18, 19, 286 
21) Retrospective cohort analysis suggests that Kanamycin use is associated with less 287 
ototoxicity than amikacin. (21)    288 
There are few recent MDR-TB studies investigating hearing loss associated with 289 
capreomycin possibly as its cost and need for electrolyte monitoring put it out of reach for 290 
many low income countries. However, although clearly defined methods for monitoring are 291 
not always described, there is a suggestion that levels of hearing loss are lower for 292 
capreomycin with proportions affected ranging from 0.7%-25%.(6, 22-25) Studies comparing 293 
amikacin to capreomycin are limited to a small retrospective study by this group which 294 
showed in univariate analysis that hearing loss was associated with amikacin use over 295 
capreomycin(10) and a pharmacovigilance reporting study showing spontaneous reports of 296 
deafness were disproportionately associated with amikacin followed by kanamycin 297 
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compared to capromycin. (26)  Our study has larger numbers than our earlier study and is 298 
not limited by reporting bias and other issues inherent in pharmacovigilance reporting. The 299 
main limitation of our study arises from the differing audiogram policies at the sites. In the 300 
hearing loss (composite) analysis there is the possibility of underestimating hearing loss 301 
caused by capreomycin due to asymptomatic cases with ototoxicity being less likely to be 302 
identified (ascertainment bias) than those in the amikacin group who had more routine 303 
audiograms. However, to counter this possible bias we performed the ototoxicity analysis 304 
including in the denominators only those who had had an audiogram within a month of 305 
ending the injectable agent. Although the numbers of patients is smaller, in this analysis, the 306 
possible bias works in the opposite direction because patients at capreomycin sites who had 307 
audiograms were more likely to be those with a perceived risk of ototoxicity. These issues 308 
probably account for the difference between the hazard ratio for the ototoxicity outcome (5 309 
times more likely with amikacin) compared to 15 times more likely for the composite 310 
hearing loss outcome with amikacin, and the real value may lie between the two numbers.  311 
We also consider that the character as well as the likelihood of occurrence of hearing loss 312 
can differ with capreomycin. The evidence for this suggestion is that the audiograms of the 313 
two patients who experienced ototoxicity on capreomycin did not display progressive 314 
hearing loss despite on-going exposure (lack of alternative drugs) which would be extremely 315 
unlikely for amikacin. (8) However, further investigations on the type of and degree of 316 
hearing loss caused by capreomycin in a randomised controlled trial is required. Reducing 317 
the proportions of patients experiencing hearing loss treated with amikacin may be possible 318 
with lower doses (7.5mg/kg) and AUC monitoring. (27) However the efficacy of this dose is 319 
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unclear and it is not currently recommended.  Other possibilities include the co-320 
administration of N-acetyl cysteine or other antioxidants,(28) and genetic testing for 321 
mutations in the mitochondrial gene encoding 12S rRNA (MT-RNR1) and avoiding 322 
aminoglycosides in these cases, (29-31) though the prevalence of these mutations is low.  323 
However, our findings support the initial use of capreomycin over amikacin as a means of 324 
reducing hearing loss. Capreomycin use first line has also been advocated for, when 325 
onwards resistance patterns are considered; amikacin activity is often spared after the 326 
evolution of capreomycin resistance but not the other way round.(32, 33)  The disadvantage 327 
of capreomycin is the associated electrolyte disturbance which led to 328 
discontinuation/switch in 14% of patients treated with it in our study. Of note, however, 329 
electrolyte abnormalities were managed effectively in all patients with no long term 330 
consequences. The association of capreomycin with electrolyte disturbance and renal 331 
impairment during treatment for TB is well reported. (13, 34, 35) In settings where regular 332 
rapid and reliable blood monitoring is not feasible, the nephrotoxicity of capreomycin may 333 
lead to deaths due to hypokalaemia and renal failure.(13, 23) Our data demonstrate that 334 
this is not the case in a well-resourced setting. 335 
In summary we provide retrospective cohort evidence of high levels of ototoxicity and 336 
hearing loss in a UK MDR-TB cohort. Hearing loss was 14 times more likely with amikacin 337 
than capreomycin, while capreomycin was associated with electrolyte disturbance leading 338 
to cessation of the drug in 14% of those treated with it.  Given the significance and  339 
irreversibility of hearing loss, in settings where blood monitoring is possible, we would 340 
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favour starting with capreomycin rather than amikacin, until such time as short course and 341 
injectable drug -free regimens incorporating the newer drugs have been shown to be 342 
effective .(17) 343 
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 483 
 Table 1: Ototoxicity and Hearing loss (composite) definitions 484 
 485 
 Hearing loss No hearing loss Unable to classify 
Ototoxicity 
 
 
 
A significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
before or during therapy and one 
performed later during therapy or 
after completing therapy in the 
presence of normal 
tympanograms.* 
A normal audiogram in the last 
month or after completing 
injectable therapy.* 
An abnormal audiogram 
without an earlier audiogram 
for comparison* 
 No significant deterioration (ASHA 
criteria) between an audiogram 
performed in the last month or after 
injectable therapy stopped and one 
performed within the first month of 
therapy.*  
A normal final audiogram 
before the last month of 
therapy (unless performed 
after 365 days on therapy). 
No significant deterioration (ASHA 
criteria) between an audiogram 
performed after 365 days of 
injectable therapy and one 
performed within the first month of 
therapy. 
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Hearing loss (composite)  
 
 
 
As for ototoxicity No report of ‘hearing impairment’ or 
‘tinnitus’ and does not fit the criteria 
for ototoxicity. 
Unable to report symptoms 
(intubated, extreme psychosis) 
or full set of medical or nursing 
notes missing. 
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with an 
abnormal audiogram. No prior 
audiogram required.   
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with a normal 
audiogram or no deterioration in 
audiograms performed within a 
month of starting and at the time or 
after the onset of symptoms.  
 
A clinical report of new ‘hearing 
impairment’ or ‘tinnitus’ during or 
after therapy with an injectable 
agent in association with a 
significant deterioration (ASHA 
criteria)  between an audiogram 
performed before or during therapy 
and one performed later during 
therapy or after completing therapy 
above 8khz range.  
  
Worsening ototoxicity 
after stopping injectable 
agent 
A significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
30 days or more after the end of 
injectable therapy to one 
performed in the month before the 
end of therapy or on the stop date. 
No significant deterioration (as 
determined by ASHA criteria) 
between an audiogram performed 
30 days or more after the end of 
injectable therapy to one performed 
in the month before the end of 
therapy or on the stop date. 
Any case not fitting either of 
the definitions.  
PTA= pure tone audiometry, Normal audiogram=all frequencies better than 25 dB, abnormal 486 
audiogram = ASHA criteria, ASHA=American speech and Hearing Association. *based on 487 
definitions of hearing loss proposed by Seddon et al 20129  488 
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Table 2: Background characteristics and demographics of patients (n=93) 489 
Characteristic Number (% unless otherwise indicated) 
Median age in months (IQR*) (n=93)  28 (24-38) 
Male gender (n=93)  64 (68) 
HIV infected (n=93)  5 (5) 
Country of birth (n=93) UK 9 (10) 
 Western and Northern Europe other  1 (1) 
 Chinese subcontinent 10 (10) 
 Indian subcontinent 36 (38) 
 Africa 15 (16) 
 Eastern Europe + Russia 22 (24) 
Type of TB (n=93) MDR-TB 73 (78) 
 MDR-TB +FLQr**  12 (13) 
 XDR-TB 8 (9) 
Location of TB (n=93) Pulmonary 41 (44) 
 Extra-pulmonary only 31 (33) 
 Both pulmonary and extra-pulmonary 21 (23) 
Injectable agent (n=93) Capreomycin 31 (33) 
 Amikacin 43 (46) 
 Amikacin and capreomycin (sequentially, 
either order) 
18 (19) 
 Amikacin followed by streptomycin  1 (1) 
Baseline creatinine µmol/L (n=87)(IQR)  66 (58-75) 
Creatinine clearance (n=81, median/IQR)  116.2 (75.7, 179.1) 
Median initial dose of injectable agent 
(mg/kg) (n=82) (IQR) 
 14.81 (14.06-16.13) 
Median number of Amikacin troughs/week 
(those on amikacin) (n=58) (IQR) 
 1.01 (0.76-1.29) 
*IQR-interquartile range, FLQr=fluroquinolone resistance. 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
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Table 3: Multivariable (adjusted) analysis investigating the predictors of hearing loss (composite)  505 
   Univariate analysis Multivariable analysis 
VARIABLES 
Hearing 
loss (%) 
 
n=34 
(38%) 
No 
hearing 
loss (%) 
n=56 
(62%) 
Hazard ratio p 
Hazard ratio p 
Choice at 
start:  
 
Amikacin (n=53) 
versus 
Capreomycin (n=37) 
29 (55) 24 (45) 5.80(2.23-15.04) <0.001  
5* (14) 32 (86) 
Grouping  
 
 
Starting amikacin (n=53) 
versus 
Capreomycin only (n=30) 
29 (55) 24 (45) 11.70 (2.78-49.20) 0.001 13.85 (3.25-58.99) <0.001 
2 (7) 28 (93) 
Capreomycin followed by 
amikacin (n=7) 
versus 
Capreomycin only (n=30) 
3 (43) 4 (57) 6.29 (1.05-37.65) 0.044 4.03 (0.66-24.63) 0.13 
2 (7) 28 (93) 
Starting amikacin (n=53) 
versus 
Capreomycin followed by 
amikacin (n=7) 
29 (55) 24 (45) 1.86 (0.56-6.13) 0.307 3.44 (0.97-12.18) 0.06 
3 (43) 4 (57) 
MDR-TB 
Type 
MDR+ FLQ-TB (n=12) 
versus 
MDR-TB (n=70) 
8 (67) 4 (33) 3.26(1.44-7.36) 0.005  
22 (31) 48 (69) 
XDR-TB (n=8) 
versus 
MDR TB (n=70) 
4 (50) 4 (50) 1.62 (0.55-4.73) 0.378 
22 (31) 48 (69) 
XDR-TB (n=8) 
versus 
MDR+FLQ-TB (n=12) 
4 (50) 4 (50) 0.55 (0.17-1.83) 0.331 
8 (67) 4 (33) 
FLQ resistance (n=20)  
versus 
MDR TB (n=70) 
12 (60) 8 (40) 2.43 (1.20-4.93) 0.013 3.15(1.45-6.88) 0.004 
22 (31) 48 (69) 
Median dose of injectable at start 
(mg/kg) (IQR) 
14.58 
(13.82-
15.51) 
14.94 
(14.07-
16.63) 
0.84 (0.71-1.00) 0.047  
Median creatinine baseline µmol/L (log 
scale) 
4.25(4.13, 
4.30) 
4.17 
(4.04, 
4.32) 
4.37 (1.12-17.11) 0.034 
Median creatinine clearance 
114.1 
(99.5, 
122.9) 
119.3 
(105.8-
134.5) 
0.98 (0.97, 1.00) 0.055 0.99 (0.97-1.00) 0.11 
Median Age (1 year effect) (IQR) 
28.5 (25-
39) 
27.5 
(22.5-
33.5) 
1.03 (0.99-1.07) 0.127  
*Only two of these cases occurred on capreomycin. The other three occurred on amikacin after they 506 
had been switched off capreomycin for other reasons. 2 had normal pure tone audiograms (PTA) at 507 
the start of amikacin. 508 
 509 
 510 
 511 
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Table 4: Multivariable model for creatinine rise to over 1.5 times baseline and 512 
hypokalaemia 513 
 MV model for cratinine rise > 1.5x 
baseline 
MV model for hypokalaemia 
variable Odds Ratios P value Odds ratios P value 
Creatinine baseline 1.02 (0.99-1.05) 0.145  
Amikacin verses 
capreomycin at 
start 
0.44 (0.14-1.45) 0.178 0.28 (0.11-
0.72) 
0.008 
Total duration (30 
days effect) 
1.15 (1.02-1.32) 0.040 1.00 (0.91-
1.08) 
0.869 
 514 
 515 
 516 
 517 
Figure 1: Flow diagram showing injectable agent use in cohort 518 
 519 
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 520 
 521 
Figure 2: Predicted proportion surviving without hearing loss by initial choice of injectable 522 
agent. Middle line (black) represents the predicted proportion and outer lines represent 523 
95% confidence intervals (red).  524 
 525 
 526 
 527 
 528 
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